Menu Close

Walter Public Investments Inc. Makes New Investment in Johnson & Johnson (NYSE:JNJ)

view original post

Walter Public Investments Inc. acquired a new position in shares of Johnson & Johnson (NYSE:JNJGet Rating) during the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 84,758 shares of the company’s stock, valued at approximately $15,726,000. Johnson & Johnson accounts for about 5.3% of Walter Public Investments Inc.’s holdings, making the stock its 7th biggest position.

Other hedge funds also recently made changes to their positions in the company. Magnolia Capital Management Ltd. raised its position in shares of Johnson & Johnson by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $1,978,000 after purchasing an additional 55 shares during the last quarter. Howard Financial Services LTD. grew its stake in Johnson & Johnson by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after acquiring an additional 57 shares during the period. American Financial Advisors LLC grew its stake in Johnson & Johnson by 2.1% in the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock worth $481,000 after acquiring an additional 57 shares during the period. Capital Investment Counsel Inc grew its stake in Johnson & Johnson by 0.8% in the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after acquiring an additional 59 shares during the period. Finally, Kwmg LLC grew its stake in Johnson & Johnson by 2.6% in the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after acquiring an additional 59 shares during the period. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $172.92 on Wednesday. The firm has a market capitalization of $455.02 billion, a P/E ratio of 25.17, a P/E/G ratio of 3.32 and a beta of 0.59. The company’s fifty day moving average price is $175.67 and its two-hundred day moving average price is $174.49. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.48 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Insider Activity

In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent analyst reports. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. UBS Group lowered their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Citigroup lowered their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Finally, Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating for the company. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $189.89.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.